Thus, in this study, we proposed for the first time the dual inhibition of GSK3β and PDE7 as a therapy for PPMS by analyzing the neuroprotective, anti-inflammatory and neurorepairing activity of VP3.15. Here, PDE7A is linked to primary progressive multiple sclerosis.